Objectives-Women with high mammographic breast density are at increased risk of breast cancer. This study explores whether these women should receive intensified screening (more frequent screening or screening with alternative techniques that increase the length of the preclinical detectable phase) to reduce further breast cancer mortality. Methods-Mathematical models were used to estimate the eVects of intensified screening in women with high breast density. The eVects were expressed as a reduction in the number of interval cancers.
High mammographic breast density is one of the strongest breast cancer risk factors known to date. 1 This observation has led many investigators to recommend more frequent screening for women with high breast density. [2] [3] [4] [5] Furthermore, it is expected that these women will benefit from alternative screening methods that lengthen the preclinical detectable phase. These methods might consist of taking additional mammographic views 6 or using other techniques, such as digital mammography 7 and magnetic resonance imaging (MRI). 8 High mammographic breast density is mostly seen in young women; breast density often diminishes around the menopause. 9 However, around the menopause more and more women start to use hormone replacement therapy, which may strongly increase breast density. 10 Consequently, many women at screening ages may still have high breast density.
No studies have been reported of the eYcacy of intensified screening particularly aimed at women with dense breasts. An experimental study would take a long time but, as an interim solution, the potential impact of intensified screening can be modelled. We modelled the potential impact on the basis of contemporary research evidence, such as the strength of the relation between breast density and breast cancer risk, as reported in published work. For this purpose, evidence was also needed on the prevalence of various breast patterns in a screening population, as well as estimated mean lead times (the time that the diagnosis of a tumour is advanced by screening) in women with various breast patterns.
Methods
We used mathematical models (appendix 1) to estimate the number of interval cancers (tumours emerging in, for example, the two year interval period between two screening examinations) and the number of screen detected cancers (tumours detected at screening) under various screening scenarios. 11 The eVects of more frequent screening were expressed as the reduction in the total number of interval cancers, as a ranking for a reduction in mortality-the higher the reduction in interval cancers, the higher the mortality reduction.
To use these models, data are needed on breast cancer incidence rates and on mean lead times in women with various breast patterns. The mean lead time, which reflects the length of time tumours spend in a detectable phase, is thought to be dependent on the breast pattern because tumours may be more diYcult to detect in breasts with high rather than low mammographic density. [12] [13] [14] The mean lead time also depends on tumour growth rate, but it is not yet clear whether tumours in diVerent breast density patterns also show diVerent growth rates.
Besides more frequent screening, the use of alternative screening techniques that increase the preclinical detectable phase may also lead to a reduction in interval cancers. From the models in appendix 1, we could infer the mean lead times that need to be achieved by these alternative screening techniques to gain the same reduction in interval cancers as that accomplished with more frequent screening.
To obtain estimates for the variables needed in the models we used the characteristics of the Dutch screening population, aged 50-69 years. 15 We grouped the breast density patterns in this population according to a four category classification, defined by the proportion of the breast that is composed of mammographic density: <5%, 5-25%, 26-75%, or >75%. The prevalence of each of the four density categories (table 1) was estimated on the basis of the age distribution of the screening population 15 and the distribution of breast patterns according to age, as in a previous study. 9 The incidence of breast cancer in each breast density category was estimated on the basis of the total breast cancer incidence (3.3/1000 a year 15 16 ), the prevalence of the various breast density categories (table 1), and the relative breast cancer risks for various categories of breast density compared with minimal breast density. These relative risks were obtained from recently published work on the eVect of breast density on breast cancer risk 4 5 (table 1) .
Information on mean lead times was estimated from the proportion of screen detected cancers among the total number of screen detected and interval cancers, as actually observed in a screening programme. In our example we used observations from rounds 5-10 of the Nijmegen breast cancer screening programme in the Netherlands. These data were used to obtain maximum likelihood estimates for 1/mean lead time (table 1) . 11 In appendix 2 we present a simplified formula (deducible from the formulae in appendix 1) on which the maximum likelihood estimates were based.
In the Nijmegen screening programme we observed a diVerence in the proportion of interval cancers between various breast patterns, 17 but the separate eVects of sensitivity of the screening test and tumour growth rates on this proportion could not be distinguished. This is one of the reasons that the calculations in table 1 and the formulae in the appendices are based on the assumption that the sensitivity is equal to 1 for all breast patterns and that only the mean lead time is allowed to vary between breast patterns. (Sensitivity is defined here as the probability φ, with 0<φ<1, that the screening test correctly identifies subjects who are in the preclinical detectable phase.) This assumption also keeps the arithmetic and estimation procedures as simple as possible. The assumption that the sensitivity is equal to 1 is obviously unrealistic. However, we would like to emphasise that the estimates for the mean lead time and the sensitivity are strongly negatively correlated and hard to separate. In the paper that describes these models in detail, 11 these correlations vary from −0.94 to −0.82 for various models. As a consequence of this strong negative correlation, we can compensate a (wrongly) assumed sensitivity of 1 with a somewhat lower value for the mean lead time.
To estimate the eVect of intensified screening in women with dense breasts we assumed that our screening population was a cohort of 100 000 women who were screened during an arbitrarily chosen period of six years. For this cohort we estimated the impact of annual instead of biennial screening. For reasons of simplicity, we further assumed that compliance with the screening programme was 100%, that no one entered the cohort after the start of follow up, and that there was no loss of follow up due to death or migration. Moreover, we assumed that the risk status of the women remained unchanged from the time of their first screening examination. Table 2 presents the results of six years' follow up of the hypothetical cohort. The table indicates that annual instead of biennial screening becomes more eYcient in cases of higher breast density. It can be seen that in the Results are based on data obtained from the Dutch screening population 15 16 and from the Nijmegen screening programme, 9 and on relative risk estimates obtained from published work. 4 5 lowest breast density category 2107 additional examinations are needed to prevent one breast cancer from occurring in the interval. In the highest breast density category, only 242 additional examinations are needed to attain the same goal. We considered the following screening strategies in comparison with biennial screening for all women:
Results
(1) Only women in the highest density category (>75% density) are screened annually. All other women are screened biennially. (2) Women in the two higher breast density categories (>25% density) are screened annually. All other women are screened biennially. (3) All women with slightly to strongly increased density (>5% density) are screened annually. Those in the lowest breast density category are screened biennially. (4) All women are screened annually.
For the above mentioned screening strategies we computed the reduction in the total number of interval cancers in proportion to the total number of interval cancers for biennial screening-that is, 669 (table 2). This reduction was set out against the factor by which the number of screening examinations had to be multiplied to attain this reduction, compared with biennial screening (fig 1) . If all women were screened biennially, the number of screening examinations would be 297 289 (table 2) .
Although annual screening seemed to be most eYcient in women with the highest breast density, fig 1 shows that with strategy 1 only a 4% reduction can be attained in the total number of interval cancers (table 2: 24/669). For this purpose an increase in examinations by a factor of 1.02 is needed (table 2: (297 289 + 5815)/297 289). With strategy 2 an 18% reduction can be accomplished, against an increase in the number of screening examinations by a factor of 1.2. In the same way, it can be observed that with strategy 3 the reduction is 36%, against an increase in the number of screening examinations by a factor of 1.7. In strategy 4, doubling the number of examinations yields a 43% reduction in the total number of interval cancers.
Instead of oVering women annual conventional film screen mammography, the use of alternative screening techniques that lengthen the preclinical detectable phase may be considered. From the formula in appendix 2 (which can be deduced from the formulae in appendix 1) it can be inferred that the mean lead time must be doubled for each breast density category to gain the same proportion of screen detected cancers in the total number of screen detected plus interval cancers, and thus, the same reduction in interval cancers as with annual screening. This means that mean lead time estimates in table 1 have to be doubled to 6.8 years for women with <5% density, 5 years for those with 5-25% density, 3.8 years for those with 26-75% density, and 1.8 years for women with >75% density.
Discussion
If only women with >75% density were screened annually, this would yield only a small reduction in the number of interval cancers in the total population screened. To reduce the total number of interval cancers by a reasonable proportion, all women with >25% density (18% reduction) would have to be screened annually.
We attempted to estimate the reduction in the number of interval cancers that might be accomplished by more frequent screening in a Dutch screening population. Whether this reduction can be obtained in practice depends largely on the accuracy of our estimates of relative risk, breast pattern distribution, and mean lead times. In particular, the distribution of breast density patterns, which was obtained from a Dutch screening population, may diVer from that in other countries. DiVerences in the prescription patterns of hormone replacement therapy may be an explanation for this, because hormone replacment therapy use may strongly increase breast density. 10 To rate the true value of the impact of more frequent screening we should estimate the reduction in breast cancer mortality instead of the reduction in interval cancer rates. For this purpose, evidence is needed of the exact relation between breast density, on the one hand, and tumour growth rates and prognostic characteristics, on the other. Such evidence, however, is not yet available from published work. Whether more frequent screening in women with dense breasts is desirable or not, will depend to a large extent on the side eVects and costs. Side eVects of more frequent screening may be increased breast cancer risk, owing to higher radiation exposure. Although there seems to be little risk of breast cancer associated with annual mammography in women over the age of 35, it has also been suggested that proliferating cells (which are thought to cause high mammographic breast density) are more susceptible to radiation carcinogenesis. 18 Therefore, the risks of more frequent screening should be established separately in women with high mammographic density. In this study a reasonable reduction in interval cancers was found to require a large number of additional screening examinations and thus high financial costs. Financial resources could possibly be applied more eYciently if intensified screening strategies were targeted at the group of women with the highest risk of breast cancer. Such a group may consist of women whose mammographic density does not decrease naturally as they grow older, or women who have other breast cancer risk factors in addition to increased breast density.
For alternative screening techniques to be worthwhile, the mean lead times would have to be increased considerably to obtain the same results as those with annual screening. To determine whether this is possible or not, the eVects of using MRI, additional mammographic views, and digital mammography should be evaluated for screening. Although it seems unrealistic that mean lead times can be achieved that are twice as long as the current mean lead times, expectations for MRI are high. However, this technique is probably too expensive to use on all women with moderately to strongly increased breast density, and probably not suYciently specific without the additional use of mammography. 19 In addition to more frequent screening, preventive strategies have also been proposed for women with high mammographic breast density. 20 21 The administration of gonadotrophin-releasing hormone agonists 20 or the anti-oestrogenic agent, tamoxifen 22 and the adoption of a low fat, high carbohydrate eating pattern 21 seemed to reduce mammographic breast density. Most trials that study the eYcacy of chemopreventives are still in an initial phase. 20 21 One trial has recently shown a strong reduction in breast cancer incidence with the prophylactic use of tamoxifen. 23 This could not be confirmed in other trials, however. 24 25 If, in the future, the chemopreventive strategies appear to be eVective, this eVect may be twofold: through a reduction in breast density chemopreventives might both facilitate the early detection of cancer and reduce breast cancer incidence.
Conclusions
At present, there is no tailor-made screening strategy for women with high breast density. More frequent screening examinations may be useful, but they will also be costly. If in future research additional mammographic views or digital mammography can prolong mean lead times, these strategies may be a good and, possibly cheaper, alternative.
